Second Look Lab — Research Brief: Two approved-drug routes to reducing glial encapsulation of implanted neural electrodes

Hypothesis-generating brief from Second Look Lab, an independent drug-repurposing project. Not medical advice; no human dosing is proposed and no claim of efficacy in humans is made. Chronic intracortical electrodes fail largely because the brain encapsulates them, and almost all effort on this problem is directed at materials, geometry and coatings. We instead searched for a systemically administered, already-approved drug with a measured effect on that encapsulation and no clinical follow-up. Route 1: NHE-1 inhibition. PMID 33621208 (J Neural Eng, 2021) reported that systemic HOE-642 (cariporide) reduced microglial encapsulation of implanted intracortical microelectrodes from 50.7 +/- 6.0% to 8.9 +/- 6.1% at 5 h, and the activation radius from 222.2 to 177.9 um at 72 h, with no effect on migration rate. There has been no follow-up in five years. Cariporide itself is not approved and its cardiac-surgery programme ended with an excess of cerebrovascular events. Rimeporide, a different NHE-1 inhibitor, has completed a Phase 1 study in humans (NCT02710591) and has been tested side by side with HOE-642 in mouse brain after ischaemic stroke (PMID 37686096), with reduced neuroinflammation and improved recovery. No published work joins these three facts. Route 2, weaker and stated as such: valproic acid inhibits glial scar formation after ischaemic stroke (PMID 35316816), and as of 21 November 2026 ClinicalTrials.gov lists no registered trial of valproic acid in glial scar or in neural implants. Eight weaknesses are stated by the authors in the brief itself, including that the headline measurement is acute, that reduced encapsulation is not the same as preserved recording quality, and that cross-literature convergence is weak evidence. Method, counts of discarded candidates and the reasons for each discard are given in the brief. Register of checked and rejected ideas: https://secondlooklab.pages.dev

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24422856
Primary Topic
Neuroscience and Neural Engineering
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Second Look Lab — Research Brief: Two approved-drug routes to reducing glial encapsulation of implanted neural electrodes

Second Look Lab
Zenodo (CERN European Organization for Nuclear Research)
Neuroscience and Neural Engineering
preprint

Second Look Lab — Research Brief: Two approved-drug routes to reducing glial encapsulation of implanted neural electrodes

Second Look Lab
preprint en

Abstract

Hypothesis-generating brief from Second Look Lab, an independent drug-repurposing project. Not medical advice; no human dosing is proposed and no claim of efficacy in humans is made. Chronic intracortical electrodes fail largely because the brain encapsulates them, and almost all effort on this problem is directed at materials, geometry and coatings. We instead searched for a systemically administered, already-approved drug with a measured effect on that encapsulation and no clinical follow-up. Route 1: NHE-1 inhibition. PMID 33621208 (J Neural Eng, 2021) reported that systemic HOE-642 (cariporide) reduced microglial encapsulation of implanted intracortical microelectrodes from 50.7 +/- 6.0% to 8.9 +/- 6.1% at 5 h, and the activation radius from 222.2 to 177.9 um at 72 h, with no effect on migration rate. There has been no follow-up in five years. Cariporide itself is not approved and its cardiac-surgery programme ended with an excess of cerebrovascular events. Rimeporide, a different NHE-1 inhibitor, has completed a Phase 1 study in humans (NCT02710591) and has been tested side by side with HOE-642 in mouse brain after ischaemic stroke (PMID 37686096), with reduced neuroinflammation and improved recovery. No published work joins these three facts. Route 2, weaker and stated as such: valproic acid inhibits glial scar formation after ischaemic stroke (PMID 35316816), and as of 21 November 2026 ClinicalTrials.gov lists no registered trial of valproic acid in glial scar or in neural implants. Eight weaknesses are stated by the authors in the brief itself, including that the headline measurement is acute, that reduced encapsulation is not the same as preserved recording quality, and that cross-literature convergence is weak evidence. Method, counts of discarded candidates and the reasons for each discard are given in the brief. Register of checked and rejected ideas: https://secondlooklab.pages.dev

Zenodo (CERN European Organization for Nuclear Research)
Neuroscience and Neural Engineering
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Second Look Lab — Research Brief: Two approved-drug routes to reducing glial encapsulation of implanted neural electrodes — Second Look Lab · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS